Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $79 and keeps an Outperform rating on the shares. The company’s strong Q2 sales lead to a 2025 guidance increase, the analyst tells investors in a research note. The firm says Livmarli continues its strong launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright
- Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals Reports Strong Q2 2025 Growth
- Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment